BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...pump inhibitor (PPI) Helicobacter pylori infection Ph III data 3Q14 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL)/Scolr Pharma Inc....
BioCentury | Mar 17, 2014
Company News

RedHill, Temple University deal

...IP covering the company's RHB-102 . In 2010, RedHill licensed patents from the now defunct Scolr Pharma Inc....
...Scolr, which has been terminated, but RedHill declined to disclose details. Under the 2010 deal, Scolr...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Jul 29, 2013
Clinical News

RHB-102 regulatory update

...of ondansetron, a serotonin (5-HT3) receptor antagonist. RedHill has exclusive, worldwide rights to RHB-102 from Scolr...
...2010 deal (see BioCentury, May 17, 2010). RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Mar 4, 2013
Clinical News

RHB-102 regulatory update

...of ondansetron, a serotonin (5-HT3) receptor antagonist. RedHill has exclusive, worldwide rights to RHB-102 from Scolr...
...to prevent chemotherapy-induced nausea and vomiting (CINV). RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Apr 23, 2012
Clinical News

RHB-102: Final pivotal trial data

...meeting with FDA in the coming weeks. RedHill has exclusive, worldwide rights to RHB-102 from Scolr...
...Zofran to prevent chemotherapy-induced nausea and vomiting (CINV). RedHill Biopharma Ltd. (Tel Aviv:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Feb 20, 2012
Clinical News

RHB-102: Phase III started

...company said results are expected within "several months." RedHill has full rights to RHB-102 from Scolr...
...Zofran to prevent chemotherapy-induced nausea and vomiting (CINV). RedHill Biopharma Ltd. (Tel Aviv:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Jul 4, 2011
Financial News

Scolr Pharma completes private placement of convertible debentures and warrants

...debentures and warrants Raised: $189,000 Placement agent: Taglich Brothers Shares outstanding prior: 49.8 million Note: Scolr...
BioCentury | Jun 27, 2011
Financial News

Scolr Pharma completes private placement of convertible debentures and warrants

Scolr Pharma Inc. (OTCBB:SCLR), Bothell, Wash. Business: Drug delivery Date completed: 6/16/11 Type: Private placement of convertible debentures and warrants Raised: $1 million Shares outstanding prior: 49.8 million Note: The senior secured debentures bear 8%...
BioCentury | May 16, 2011
Company News

Scolr Pharma drug delivery news

...in cash. The company declined to comment further on possible financings or its future plans. Scolr...
...its Controlled Delivery Technology (CDT) to develop extended-release solid oral pharmaceutical medications and nutritional supplements. Scolr Pharma Inc....
Items per page:
1 - 10 of 47
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...pump inhibitor (PPI) Helicobacter pylori infection Ph III data 3Q14 RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL)/Scolr Pharma Inc....
BioCentury | Mar 17, 2014
Company News

RedHill, Temple University deal

...IP covering the company's RHB-102 . In 2010, RedHill licensed patents from the now defunct Scolr Pharma Inc....
...Scolr, which has been terminated, but RedHill declined to disclose details. Under the 2010 deal, Scolr...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Jul 29, 2013
Clinical News

RHB-102 regulatory update

...of ondansetron, a serotonin (5-HT3) receptor antagonist. RedHill has exclusive, worldwide rights to RHB-102 from Scolr...
...2010 deal (see BioCentury, May 17, 2010). RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Mar 4, 2013
Clinical News

RHB-102 regulatory update

...of ondansetron, a serotonin (5-HT3) receptor antagonist. RedHill has exclusive, worldwide rights to RHB-102 from Scolr...
...to prevent chemotherapy-induced nausea and vomiting (CINV). RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Apr 23, 2012
Clinical News

RHB-102: Final pivotal trial data

...meeting with FDA in the coming weeks. RedHill has exclusive, worldwide rights to RHB-102 from Scolr...
...Zofran to prevent chemotherapy-induced nausea and vomiting (CINV). RedHill Biopharma Ltd. (Tel Aviv:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Feb 20, 2012
Clinical News

RHB-102: Phase III started

...company said results are expected within "several months." RedHill has full rights to RHB-102 from Scolr...
...Zofran to prevent chemotherapy-induced nausea and vomiting (CINV). RedHill Biopharma Ltd. (Tel Aviv:RDHL), Ramat-Gan, Israel Scolr Pharma Inc....
BioCentury | Jul 4, 2011
Financial News

Scolr Pharma completes private placement of convertible debentures and warrants

...debentures and warrants Raised: $189,000 Placement agent: Taglich Brothers Shares outstanding prior: 49.8 million Note: Scolr...
BioCentury | Jun 27, 2011
Financial News

Scolr Pharma completes private placement of convertible debentures and warrants

Scolr Pharma Inc. (OTCBB:SCLR), Bothell, Wash. Business: Drug delivery Date completed: 6/16/11 Type: Private placement of convertible debentures and warrants Raised: $1 million Shares outstanding prior: 49.8 million Note: The senior secured debentures bear 8%...
BioCentury | May 16, 2011
Company News

Scolr Pharma drug delivery news

...in cash. The company declined to comment further on possible financings or its future plans. Scolr...
...its Controlled Delivery Technology (CDT) to develop extended-release solid oral pharmaceutical medications and nutritional supplements. Scolr Pharma Inc....
Items per page:
1 - 10 of 47